Free Alerts   Login
Health Care › Laboratory Analytical Instruments

HLTH Stock Price Correlated With Cue Health Financials

HLTH Stock Price vs. Quarterly
HLTH
Income Statement
Cash Flow
Balance Sheet

HLTH Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

HLTH Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

HLTH Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Tarsadia Capital
10,684,791 sh
10,684,791 sh
NEW
$1,736
$1,736
Oakmont
9,595,348 sh
 
$1,559
Madrone Advisors
7,078,566 sh
 
$1,150
Jabodon Pt
3,981,258 sh
 
$647
Goldman Sachs Group
3,926,890 sh
3,895,774 sh
12520%
$638
$624
Vanguard Group
3,884,285 sh
 
$631
Temasek Holdings (Private)
3,125,000 sh
 
$508
Blackrock.
1,572,585 sh
-66,404 sh
-4%
$255
-$470
Geode Capital Management
1,038,864 sh
13,817 sh
1%
$169
-$284
Bleichroeder Lp
1,000,000 sh
 
$163
Jacobs Levy Equity Management
940,301 sh
-187,217 sh
-17%
$153
-$346
Verition Fund Management
861,400 sh
-12,700 sh
-1%
$140
-$247
D. E. Shaw & Co..
476,733 sh
-193,684 sh
-29%
$77
-$220
Renaissance Technologies
466,600 sh
142,800 sh
44%
$0
Citadel Advisors
Call options for 449,600 sh
449,200 sh
112300%
$73
Msd Partners,
395,248 sh
 
$64
State Street
330,924 sh
 
$54
Koch Industries
251,472 sh
-1,956,051 sh
-89%
$41
-$935
Millennium Management
250,471 sh
-111,267 sh
-31%
$41
-$119
Invesco.
237,134 sh
65 sh
0%
$39
-$66
COMPANY PROFILE
BUSINESS AND BASIS OF ACCOUNTING Organization and Description of Business

Cue Health Inc. (the “Company”) was originally formed in the State of California on January 26, 2010, prior to being incorporated in the State of Delaware on December 14, 2017. The Company is a healthcare technology company committed to revolutionizing the healthcare experience by providing individuals with a convenient and connected diagnostic platform that bridges the physical and virtual care continuum. The Company’s proprietary platform, the Cue Health Monitoring System, comprised of the Cue Reader and Cue Test Kit, enables lab-quality diagnostics-led care at home, at work or at the point of care. This platform is designed to empower stakeholders across the healthcare ecosystem, including individuals, enterprises, healthcare providers and payors, and public health agencies with paradigm-shifting access to diagnostic and health data to inform care decisions. The Company’s headquarters are located in San Diego, California.

Basis of Presentation

The accompanying unaudited interim condensed financial statements should be read in conjunction with the audited annual financial statements and notes thereto for the year ended December 31, 2021. The unaudited interim condensed balance sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results for the fiscal year ending December 31, 2022 or any future interim period. The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”), applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for interim reporting and, in the opinion of management, include all adjustments necessary for the fair statement of the Company’s financial position for the periods presented. All such adjustments are of a normal, recurring nature. Certain disclosures have been condensed or omitted from the interim condensed financial statements. The preparation of the accompanying financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, income and expenses as well as the related disclosure of contingent assets and liabilities.

Initial Public Offering

On September 28, 2021, the Company completed its initial public offering (“IPO”) of 14,375,000 shares of the Company common stock at an offering price of $16.00 per share, including 1,875,000 shares purchased pursuant to the exercise in full of the underwriters’ option to purchase additional shares. The Company received aggregate net proceeds of approximately $206.0 million after deducting underwriting commissions and legal, accounting, and consulting fees related to the IPO.

Upon completion of the IPO, Convertible Notes outstanding, see Note 10, Debt , in the principal amount of $235.5 million and accrued interest of $2.8 million were automatically converted into 18,611,914 shares of common stock. All outstanding shares of the Company’s redeemable convertible preferred stock, see Note 11, Capital Stock , were converted into 83,605,947 shares of common stock. Immediately prior to the IPO, all of the Company’s outstanding warrants to purchase redeemable convertible preferred stock were converted into the redeemable convertible preferred stock and the related warrant liabilities were reclassified to additional paid-in capital.

Use of Estimates

The preparation of the accompanying unaudited interim condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materi

Free historical financial statements for Cue Health Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 10 quarters since 2021. Compare with HLTH stock chart to see long term trends.

Data imported from Cue Health Inc. SEC filings. Check original filings before making any investment decision.